[HTML][HTML] Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches …

FADM Opo, M Moulay, A Zari, A Alqaderi… - Frontiers in …, 2022 - frontiersin.org
Alterations to the EGFR (epidermal growth factor receptor) gene, which primarily occur in the
axon 18–21 position, have been linked to a variety of cancers, including ovarian, breast …

Epidermal growth factor receptor (EGFR) structure‐based bioactive pharmacophore models for identifying next‐generation inhibitors against clinically relevant EGFR …

PS Panicker, AR Melge, L Biswas… - Chemical biology & …, 2017 - Wiley Online Library
Present work elucidates identification of next generation inhibitors for clinically relevant
mutations of epidermal growth factor receptor (EGFR) using structure‐based bioactive …

[HTML][HTML] Computational virtual screening and structure-based design of some epidermal growth factor receptor inhibitors

MT Ibrahim, A Uzairu, S Uba… - Future Journal of …, 2020 - Springer
Background The foremost cause of cancer mortality worldwide was lung cancer. Lung
cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). The …

[HTML][HTML] Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R …

L Wang, X Huang, S Xu, Y An, X Lv, W Zhu, S Xu, Y Tu… - BMC chemistry, 2024 - Springer
Background Facing the significant challenge of overcoming drug resistance in cancer
treatment, particularly resistance caused by mutations in epidermal growth factor receptor …

[HTML][HTML] In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 1

Z Shi, J Chen, X Guo, L Cheng, X Guo… - Journal of Cancer …, 2018 - journals.lww.com
Background: The receptor tyrosine kinase of the epidermal growth factor receptor (EGFR,
ErbB) family played an important role in multisignaling pathways, which controlled …

Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis

A Sudha, P Srinivasan… - Journal of Receptors and …, 2015 - Taylor & Francis
Epidermal growth factor receptor (EGFR) protein tyrosine kinases are over expressed in
several human cancers and considered as a promising target for developing novel …

[HTML][HTML] In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

MAA Noor, MM Haq, MAR Chowdhury, H Tayara… - Pharmaceuticals, 2024 - mdpi.com
Targeting epidermal growth factor receptor (EGFR) mutants is a promising strategy for
treating non-small cell lung cancer (NSCLC). This study focused on the computational …

[HTML][HTML] Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

S Wang, X Xu, C Pan, Q Guo, Q Li, S Wan, Z Li… - International Journal of …, 2024 - mdpi.com
Epidermal growth factor receptor (EGFR) inhibitors have been used in clinical for the
treatment of non-small-cell lung cancer for years. However, the emergence of drug …

Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations

MA Ashiru, SO Ogunyemi, OR Temionu… - Journal of Molecular …, 2023 - Springer
Context As a member of a large family of proteins that together regulate various aspects of
cell growth and development, the epidermal growth factor receptor (EGFR) is a validated …

[HTML][HTML] Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation

AA Radwan, F Alanazi, A Al-Dhfyan - Plos one, 2024 - journals.plos.org
Epidermal growth factor receptor EGFR inhibitors are widely used as first line therapy for the
treatment of non-small-cell lung cancer (NSCLC) in patients harboring EGFR mutation …